Physician profile
Michael A Williamson
NPI 1770091571
$3,690.10
in general payments reported to CMS, 2019-2025
37 companies · $823 in 2025
The $823 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $593 · 2023: $786 · 2024: $1,250 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.64 |
| Education | $115.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.39 | 2021-2025 | |
| Novo Nordisk INC | $315.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $301.80 | 2023-2025 | Zepbound, Mounjaro, Trulicity |
| Ardelyx, INC. | $278.78 | 2022-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $234.24 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.95 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $163.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $138.88 | 2024-2025 | Veozah |
| Grifols USA, LLC | $127.48 | 2024-2025 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $109.55 | 2022-2023 | Injectafer |
| Boston Scientific Corporation | $104.65 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $86.37 | 2023-2025 | Repatha, Otezla, Avsola |
| Phathom Pharmaceuticals, INC. | $81.32 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $73.69 | 2022 | |
| Corium, LLC | $68.62 | 2023 | Adlarity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.